Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2010

01-10-2010 | Clinical Trial Report

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

Authors: Manabu Shiozawa, Makoto Akaike, Nobuhiro Sugano, Kazuhito Tsuchida, Naoto Yamamoto, Soichiro Morinaga

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2010

Login to get access

Abstract

Purpose

A combination of irinotecan with continuous infusional 5-fluorouracil (5-FU) is the standard treatment for advanced colorectal cancer. The aim of this study was to determine the efficacy and safety of combining irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.

Methods

Irinotecan was administered as an intravenous infusion at a dose of 120 mg/m2 on day 1 and 15. And S-1 was administered orally on days 1–14 of a 28-day cycle. S-1 was given orally at a dose that did not exceed 40 mg/m2 based BSA: BSA < 1.25 m2, 40 mg twice daily; 1.25–1.5 m2, 50 mg twice daily, and BSA > 1.5 m2, 60 mg twice daily, for 14 consecutive days.

Results

A total of 38 patients were enrolled. An intent-to-treat analysis showed a complete response and partial response to occur in 13.2% and 50.0%, respectively. The disease control rate was 84.2%. The median progression-free survival and overall survival were 10.0 months and 29.1 months, respectively. The rates of grade 3/4 toxicity over 4 cycles were the following: neutropenia, 15.8%; leucopenia, 7.9%; anorexia, 15.8%; diarrhea, 10.5%. Conclusion: IRIS is an effective, well tolerated and convenient treatment regimen for patients with advanced colorectal cancer.
Literature
1.
Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19:3801–3807PubMed
2.
Sargent DJ, Niedzwiecki D, O’Connell MJ, Schilsky RL (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144–145CrossRefPubMed
3.
Meta-analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308
4.
De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808–815PubMed
5.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041–1047CrossRefPubMed
6.
Punt CJA (2004) New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15:1453–1459CrossRefPubMed
7.
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229–237CrossRefPubMed
8.
Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E (2005) Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: multicenter study of the Gruppo Oncologico Dell’italia Meridionale. J Clin Oncol 23:4866–4875CrossRefPubMed
9.
Kohne CH, Van Cutsem E, Bokemeyer JWC, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Ruckle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Muller L, Genicot B, Anak O, Nordlinger B (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23:4856–4865CrossRefPubMed
10.
Verso M, Agnelli G (2003) Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 21:3665–3675CrossRefPubMed
11.
Kuter DJ (2004) Thrombotic complication of central venous catheters in cancer patients. Oncologist 9:207–216CrossRefPubMed
12.
Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Tateda S, Unemi N, Fukushima M (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxy pyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602–2606PubMed
13.
Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Shirasaka T (1999) Parmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000–2005PubMed
14.
Shiozawa M, Sugano N, Tsuchida K, Morinaga S, Akaike M, Sugimasa Y (2009) A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. J Cancer Res Clin Oncol 135:365–370CrossRefPubMed
15.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMed
16.
Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y, Shirao K (2006) Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17:968–973CrossRefPubMed
17.
Tsunoda A, Yasuda N, Nakao K, Narita K, Watanabe M, Matsui N, Kusano M (2009) Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. Oncology 77:192–196CrossRefPubMed
18.
Yuki S, Komatsu Y, Sogabe S, Iwanaga I, Kudo M, Miyagishima T, Nakamura M, Hatanaka K, Asaka M, Sakata Y (2009) Phase II study of combination with irinotecan and S-1(IRIS) for inoperable recurrent advanced colorectal cancer (HGCSG0302): Final analysis. Gastrointestinal Cancer Symposium. (Abstract No. 463)
19.
Mackay HJ, Hill M, Twelves C, Glasspool R, Price T, Campbell S, Massey A, Macham MA, Uzzel M, Bailey SM, Martin C, Cunningham D (2003) A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol 14:1264–1269CrossRefPubMed
20.
Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Baretta E, Lambiase A, Buzzoni R (2004) Randomized multicenter phase II trial of two defferent schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100:279–287CrossRefPubMed
21.
Grothey A, Jordan K, Kellner O, Constantin C, Dietrich G, Kroening H, Mantovani L, Schlichting C, Forstbauer H, Schmoll HJ (2004) Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectral cancer(ACRC) after failure of first-line combination therapy: results of a randomized phase II study. J Clin Oncol 22:No14S. (abstract3534)
22.
Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer:efficacy, quality-of-life and toxicity. Ann Oncol 16:282–288CrossRefPubMed
23.
Patt YZ, Lee FC, Leibmann JE, Diamandidis D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon A, Lin E (2007) Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 30:350–357CrossRefPubMed
24.
Bajetta E, Di Bartolomeo M, Buzzoni R, Mariani L, Zilembo N, Ferrario E, Lo Vullo S, Aitini E, Isa L, Barone C, Jacobelli S, Recaldin E, Pinotti G, Iop A (2007) Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomized phase II study. Br J Cancer 96:439–444CrossRefPubMed
Metadata
Title
A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer
Authors
Manabu Shiozawa
Makoto Akaike
Nobuhiro Sugano
Kazuhito Tsuchida
Naoto Yamamoto
Soichiro Morinaga
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1278-0

Other articles of this Issue 5/2010

Cancer Chemotherapy and Pharmacology 5/2010 Go to the issue

Original Article

Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis

Original Article

Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer

Original Article

A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group

Original Article

Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine

Original Article

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α

Original Article

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits